EDIT Editas Medicine, Inc. - Common Stock
$3.19
Price · Aug 19, 2026
Fundamentals as of Aug 5, 2026
52W Range
$2–$5
53% of range
Analyst Rating
BUY
18 analysts
Price Target
$6
+88% upside
P/E (TTM)
-1.8
ROE
-688.8%
Net Profit Margin
-395.0%
About Editas Medicine, Inc. - Common Stock Company overview from Wikipedia
Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
Read more
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
History
Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures. The name was changed to the current "Editas Medicine" two months later. Doudna quit in June 2014 over legal differences concerning intellectual property of Cas9.
In August 2015, the company raised $120 million in Series B funding from Bill Gates and 13 other investors. it went public on 2 February 2016, via a $94 million initial public offering.
Editas entered into a strategic collaboration with Juno Therapeutics in 2015 to create a chimeric antigen receptor and high-affinity T cell receptor therapeutics to the end of developing cancer therapeutics. Juno was later acquired by Celgene, which was in turn acquired by Bristol Myers Squibb.
The company announced in 2015 that it was planning a clinical trial using CRISPR gene editing techniques to treat Leber congenital amaurosis type 10 (LCA10), a rare genetic illness that causes blindness. On 30 November 2018, the FDA gave permission to start the trials, under the investigational name EDIT-101 (also known as AGN-151587). In September 2021, a statement from Editas claimed that preliminary results from clinical trials were promising and support clinical benefits of EDIT-101 treatment.
In March 2020, Editas, in partnership with Allergan, was the first to use CRISPR to try to edit DNA inside a person's body (in vivo). As part of the clinical trial, a patient who was nearly blind as a result of Leber's congenital amaurosis received an intravitreal injection containing a harmless virus carrying CRISPR gene-editing instructions. Five months later, Editas reworked its deal with Allergan's owner AbbVie and regained full rights to their range of eye disease treatment therapies, including EDIT-101 for the treatment of LCA10.
In 2019, the company was building new chemistry facilities in Boulder, Colorado.
Katrine Bosley was CEO until 2019, when she was replaced by board member Cynthia Collins. Collins was replaced in 2021 by James Mullen, who had been board chairman. Gilmore O'Neill, former CMO of Sarepta Therapeutics, became CEO on June 1, 2022, with Mullen staying on as executive chairman of the board.
On December 12, 2024, Editas ended the development of reni-cel and laid off 65% of its employees.
Research
Editas works with two different CRISPR nucleases, Cas9 and Cas12a.
EDIT-101 is a CRISPR based gene therapy for treatment of Leber congenital amaurosis, currently in clinical trials.
EDIT-301 is an experimental potential treatment utilizing the firm's CAS 12a editing technology for sickle cell disease and beta-thalassemia. In 2019 the firm reported early success in research on the drug;. In December 2020, it filed an IND application for treatment of sickle cell disease. In January 2021, it said it had received clearance from the FDA for phase 1 safety studies.
== References ==
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
EDIT Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$3.19
Market Cap
$312M
P/E (TTM)
-1.8
EPS (TTM)
$-1.80
Revenue (TTM)
$41M
Div Yield
—
ROE
-688.8%
Debt/Equity
2.1
52W Range
$2 – $5
EDIT Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
$41M
2016-12-31
→
2025-12-31
EPS
$-1.80
2019-12-31
→
2025-12-31
Free Cash Flow
$-166M
2016-12-31
→
2025-12-31
Margins
-395.0%
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
EDIT
Peer Median
P/E (TTM)
-1.8
17.4
P/S (TTM)
7.7
52.3
P/B
11.4
4.8
EV / EBITDA
-1.4
—
Price / FCF
-1.9
—
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
EDIT
Peer Median
Operating Margin
-394.9%
—
Net Profit Margin
-395.0%
-670.1%
ROA
-60.6%
-41.1%
ROE
-688.8%
-52.6%
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
EDIT
Peer Median
Debt / Equity
2.1
—
Current Ratio
3.5
7.7
Quick Ratio
3.5
—
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
EDIT
Peer Median
Revenue YoY
25.4%
—
Revenue CAGR 3Y
27.2%
—
Revenue CAGR 5Y
-14.9%
—
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
EDIT
Peer Median
EDIT Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
18 analysts
- Strong Buy 4 22.2%
- Buy 8 44.4%
- Hold 4 22.2%
- Sell 2 11.1%
- Strong Sell 0 0.0%
12-Month Price Target
8 analysts · 2026-08-16
Median
$5.00
Now
$3.19
Low
$1.00
High
$15.00
Median target
$5.00
+57.0%
Mean target
$6.00
+88.4%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-0.03%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| June 30, 2026 | $-0.15 | $-0.28 | 0.13% |
| March 31, 2026 | $-0.26 | $-0.27 | 0.01% |
| Dec. 31, 2025 | $-0.06 | $-0.26 | 0.20% |
| Sept. 30, 2025 | $-0.28 | $-0.30 | 0.02% |
| June 30, 2025 | $-0.63 | $-0.38 | -0.25% |
| March 31, 2025 | $-0.92 | $-0.60 | -0.32% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | — |
| CABA | $220M | -1.0 | — | — | -115.5% | — |
| VSTM | $600M | -2.6 | 209.1% | -677.6% | -449.2% | — |
| ZURA | — | — | — | — | — | — |
| MPLT | $773M | -0.9 | — | — | -151.1% | — |
| OCGN | $422M | -5.6 | 8.8% | -1537.4% | 1488.8% | — |
| PBYI | $300M | 9.8 | -0.91% | 13.6% | 26.5% | — |
| QTTB | $43M | 1.4 | — | 55.5% | 200.3% | — |
| RZLT | $388M | -4.6 | — | — | -56.9% | — |
| CMPX | $958M | — | — | — | -45.9% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 13
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| R&D Expense | $90M | $199M | $178M | $175M | $143M | $158M | $97M | $91M | $83M | $57M | |
| SG&A Expense | $50M | $72M | $70M | $71M | $76M | $68M | $65M | $55M | $51M | $46M | |
| Operating Expenses | $201M | $283M | $247M | $246M | $219M | $226M | $161M | $146M | $134M | $103M | |
| Operating Income | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M | |
| Other Non-op | $-2M | $-3.0K | $-2M | $0 | $37.0K | $16M | $-137.0K | $328.0K | $587.0K | $-57.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | |
| Net Income | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| EPS (Basic) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| EPS (Diluted) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| Shares (Basic) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| Shares (Diluted) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| EBITDA | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M |
Balance Sheet 24
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $147M | $132M | $124M | $142M | $204M | $140M | $238M | $135M | $147M | $185M | |
| Short-term Investments | $0 | $138M | $199M | $203M | $296M | $262M | $219M | $234M | $183M | · | |
| Receivables | $15M | $16M | $10M | $5M | $267.0K | $6M | $418.0K | $30.0K | $679.0K | $88.0K | |
| Prepaid Expense | $2M | $3M | $8M | $7M | $7M | $11M | $6M | $6M | $2M | $2M | |
| Current Assets | $164M | $289M | $341M | $357M | $507M | $419M | $464M | $375M | $332M | $187M | |
| PP&E (Net) | $4M | $14M | $12M | $16M | $17M | $14M | $11M | $40M | $39M | $40M | |
| PP&E (Gross) | $32M | $46M | $38M | $37M | $33M | $25M | $18M | $47M | $44M | $42M | |
| Accum. Depreciation | $28M | $32M | $26M | $22M | $16M | $11M | $7M | $7M | $4M | $2M | |
| Other Non-current Assets | $3M | $5M | $9M | $5M | $7M | $5M | $5M | $5M | $2M | $2M | |
| Total Assets | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Accounts Payable | $3M | $5M | $8M | $10M | $5M | $6M | $6M | $5M | $4M | $5M | |
| Accrued Liabilities | $33M | $46M | $35M | $31M | $20M | $24M | $22M | $13M | $11M | $17M | |
| Current Liabilities | $46M | $77M | $63M | $60M | $47M | $58M | $60M | $36M | $37M | $33M | |
| Capital Leases | $12M | $20M | $24M | $33M | $16M | $19M | $23M | $32M | $33M | $35M | |
| Other Non-current Liabilities | $3M | $3M | $2M | $0 | · | $28M | $1.0K | $293.0K | $317.0K | $396.0K | |
| Total Liabilities | $159M | $207M | $150M | $154M | $124M | $179M | $246M | $184M | $165M | $95M | |
| Long-term Debt | $59M | $57M | $0 | · | · | · | · | · | · | · | |
| Total Debt | $59M | $57M | · | · | · | · | · | · | · | · | |
| Common Stock | $10.0K | $8.0K | $8.0K | $7.0K | $7.0K | $6.0K | $5.0K | $5.0K | $4.0K | $4.0K | |
| Retained Earnings | $-1.63B | $-1.47B | $-1.23B | $-1.08B | $-858M | $-665M | $-549M | $-416M | $-306M | $-186M | |
| AOCI | $0 | $268.0K | $198.0K | $-4M | $-493.0K | $-46.0K | $107.0K | $-29.0K | $-76.0K | · | |
| Stockholders' Equity | $27M | $134M | $349M | $361M | $554M | $394M | $262M | $236M | $208M | $135M | |
| Liabilities + Equity | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Shares Outstanding | 97,866,996 | 82,734,696 | 81,767,263 | 68,847,382 | 68,435,257 | 62,563,457 | 54,355,798 | 48,758,951 | 44,507,960 | 35,818,131 |
Cash Flow 10
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $10M | $21M | $20M | $29M | $43M | $23M | $27M | $27M | $23M | $17M | |
| Restructuring | · | $12M | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $-165M | $-210M | $-132M | $-177M | $-164M | $-180M | $-41M | $-46M | $-9M | $-50M | |
| CapEx | $607.0K | $9M | $5M | $4M | $8M | $7M | $6M | $5M | $2M | $3M | |
| Investing Cash Flow | $139M | $162M | $-4M | $114M | $-54M | $-141M | $12M | $-53M | $-184M | $-3M | |
| Stock Issued | $43M | $0 | $117M | $0 | $249M | $204M | $116M | $77M | $154M | $97M | |
| Net Stock Activity | $43M | $0 | $117M | · | $249M | $204M | $116M | $77M | $154M | $97M | |
| Financing Cash Flow | $40M | $56M | $118M | $1M | $282M | $224M | $132M | $87M | $155M | $97M | |
| Net Change in Cash | $14M | $8M | $-18M | $-62M | $64M | $-96M | $103M | $-12M | $-39M | $43M | |
| Free Cash Flow | $-166M | $-219M | $-137M | $-181M | $-172M | $-187M | $-47M | $-50M | $-11M | $-53M |
Profitability 5
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| Net Margin | -395.0% | -733.7% | -196.1% | -1118.3% | -753.6% | -127.8% | -651.4% | -344.3% | · | · | |
| EBITDA Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| ROA | -60.6% | -56.4% | -30.2% | -37.0% | -30.8% | -21.4% | -28.8% | -27.7% | -40.0% | -51.3% | |
| ROE | -688.8% | -153.0% | -43.2% | -56.9% | -33.8% | -27.8% | -56.6% | -47.7% | -70.2% | -377.5% |
Liquidity & Solvency 4
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 | 7.2 | 7.7 | 10.4 | 9.1 | 5.7 | |
| Quick Ratio | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 | 7.0 | 7.6 | 10.3 | 9.0 | 5.6 | |
| Debt / Equity | 2.1 | 0.4 | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 2.0 | 0.4 | · | · | · | · | · | · | · | · |
Efficiency 2
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.1 | · | · | |
| Receivables Turnover | 2.6 | 2.4 | 10.2 | 7.3 | 8.1 | 28.1 | 91.7 | 90.1 | · | · |
Growth Rates 3
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 25.4% | -58.6% | 296.3% | -22.8% | -71.9% | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.2% | 8.2% | -4.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -14.9% | · | · | · | · | · | · | · | · | · |
Valuation (TTM) 14
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| Net Income TTM | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| Market Cap | $201M | $105M | $828M | $611M | $1.82B | $4.39B | $1.61B | $1.11B | $1.37B | $581M | |
| Enterprise Value | $113M | $-107M | · | · | · | · | · | · | · | · | |
| P/E | -1.1 | -0.4 | -5.0 | -2.8 | -9.3 | -35.4 | -11.0 | · | · | · | |
| P/S | 5.0 | 3.3 | 10.6 | 31.0 | 71.1 | 48.3 | 78.4 | 34.7 | 99.6 | 96.0 | |
| P/B | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | 6.1 | 4.7 | 6.6 | 4.3 | |
| P / Tangible Book | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | · | · | · | · | |
| P / Cash Flow | -1.2 | -0.5 | -6.3 | -3.4 | -11.1 | -24.4 | -39.6 | -24.3 | -145.2 | -11.6 | |
| P / FCF | -1.2 | -0.5 | -6.1 | -3.4 | -10.6 | -23.5 | -34.4 | -22.0 | -119.2 | -10.9 | |
| EV / EBITDA | -0.7 | 0.4 | · | · | · | · | · | · | · | · | |
| EV / FCF | -0.7 | 0.5 | · | · | · | · | · | · | · | · | |
| EV / Revenue | 2.8 | -3.3 | · | · | · | · | · | · | · | · | |
| Earnings Yield | -87.8% | -226.8% | -19.9% | -36.2% | -10.7% | -2.8% | -9.0% | · | · | · |
Income Statement 12
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12M | $3M | $25M | $8M | $4M | $5M | $31M | $61.0K | $513.0K | $1M | $60M | $5M | $3M | $10M | $7M | $42.0K | |
| R&D Expense | $20M | $18M | $27M | $20M | $16M | $27M | $49M | $48M | $54M | $49M | $70M | $41M | $30M | $38M | $52M | $41M | |
| SG&A Expense | $12M | $10M | $11M | $12M | $13M | $13M | $16M | $18M | $18M | $19M | $14M | $15M | $17M | $23M | $18M | $16M | |
| Operating Expenses | $30M | $28M | $32M | $32M | $55M | $81M | $77M | $66M | $72M | $68M | $84M | $55M | $47M | $61M | $70M | $58M | |
| Operating Income | $-19M | $-25M | $-8M | $-25M | $-52M | $-76M | $-47M | $-66M | $-72M | $-67M | $-24M | $-50M | $-44M | $-51M | $-63M | $-58M | |
| Other Non-op | $17.0K | $-113.0K | $-5.0K | $-1.0K | $-2M | $-425.0K | $-3.0K | $-5.0K | $-1.0K | $6.0K | $-13.0K | $0 | $-7.0K | $-2M | $-2.0K | $1.0K | |
| Net Income | $-18M | $-25M | $-6M | $-25M | $-53M | $-76M | $-45M | $-62M | $-68M | $-62M | $-19M | $-45M | $-40M | $-49M | $-61M | $-56M | |
| EPS (Basic) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.88 | $-0.81 | |
| EPS (Diluted) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.88 | $-0.81 | |
| Shares (Basic) | 119,294,615 | 97,879,343 | -168,811,755 | 90,090,397 | 84,412,200 | 83,055,066 | -164,396,186 | 82,485,199 | 82,310,368 | 81,938,839 | -145,983,475 | 81,648,250 | 71,376,678 | 68,924,180 | -137,197,139 | 68,736,125 | |
| Shares (Diluted) | 119,294,615 | 97,879,343 | -168,811,755 | 90,090,397 | 84,412,200 | 83,055,066 | -164,396,186 | 82,485,199 | 82,310,368 | 81,938,839 | -145,983,475 | 81,648,250 | 71,376,678 | 68,924,180 | -137,197,139 | 68,736,125 | |
| EBITDA | $-19M | $-25M | · | $-25M | $-52M | $-76M | · | $-66M | $-72M | $-67M | · | $-50M | $-44M | $-51M | · | $-58M |
Balance Sheet 24
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $182M | $124M | $147M | $166M | $139M | $139M | $132M | $96M | $64M | $69M | $124M | $83M | $221M | $129M | $142M | $211M | |
| Short-term Investments | $30M | · | $0 | $0 | $40M | $82M | $138M | $169M | $215M | $227M | $199M | $267M | $211M | $189M | · | $209M | |
| Receivables | $3M | $3M | $15M | $8M | $588.0K | $510.0K | $16M | $126.0K | $244.0K | $245.0K | $10M | $2M | $2M | $242.0K | · | $120.0K | |
| Prepaid Expense | $4M | $2M | $2M | $3M | $4M | $3M | $3M | $6M | $7M | $9M | $8M | $7M | $7M | $6M | · | $7M | |
| Current Assets | $218M | $128M | $164M | $177M | $183M | $225M | $289M | $271M | $286M | $306M | $341M | $359M | $441M | $324M | · | $427M | |
| PP&E (Net) | $3M | $3M | $4M | $4M | $5M | $8M | $14M | $15M | $14M | $13M | $12M | $12M | $13M | $13M | · | $15M | |
| PP&E (Gross) | $29M | $29M | $32M | $32M | $31M | $36M | $46M | $46M | $43M | $41M | $38M | $37M | $36M | $35M | · | $36M | |
| Accum. Depreciation | $27M | $26M | $28M | $28M | $27M | $28M | $32M | $31M | $29M | $28M | $26M | $25M | $23M | $22M | · | $20M | |
| Other Non-current Assets | $3M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $8M | $9M | $9M | $6M | $5M | $7M | · | $8M | |
| Total Assets | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | · | $531M | |
| Accounts Payable | $5M | $4M | $3M | $3M | $7M | $5M | $5M | $12M | $14M | $8M | $8M | $10M | $8M | $9M | · | $7M | |
| Accrued Liabilities | $17M | $21M | $33M | $48M | $48M | $47M | $46M | $29M | $28M | $31M | $35M | $30M | $28M | $32M | · | $19M | |
| Current Liabilities | $68M | $40M | $46M | $62M | $66M | $73M | $77M | $72M | $74M | $66M | $63M | $59M | $55M | $57M | · | $42M | |
| Capital Leases | $9M | $11M | $12M | $14M | $15M | $18M | $20M | $22M | $21M | $22M | $24M | $25M | $27M | $29M | · | $9M | |
| Other Non-current Liabilities | $2M | $3M | $3M | $5M | $5M | $6M | $3M | $3M | $4M | $3M | $2M | · | · | · | · | · | |
| Total Liabilities | $132M | $145M | $159M | $188M | $191M | $201M | $207M | $152M | $153M | $146M | $150M | $144M | $142M | $147M | · | $116M | |
| Long-term Debt | $56M | $55M | $59M | $59M | $57M | $55M | $57M | · | · | · | $0 | · | · | · | · | · | |
| Total Debt | $56M | $55M | · | $59M | $57M | $55M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $15.0K | $10.0K | $10.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $7.0K | · | $7.0K | |
| Retained Earnings | $-1.67B | $-1.65B | $-1.63B | $-1.62B | $-1.60B | $-1.54B | $-1.47B | $-1.42B | $-1.36B | $-1.29B | $-1.23B | $-1.21B | $-1.17B | $-1.13B | · | $-1.02B | |
| AOCI | $-6.0K | $0 | $0 | $0 | $15.0K | $88.0K | $268.0K | $522.0K | $-442.0K | $-326.0K | $198.0K | $-1M | $-2M | $-2M | · | $-4M | |
| Stockholders' Equity | $105M | $4M | $27M | $13M | $19M | $62M | $134M | $176M | $232M | $294M | $349M | $360M | $400M | $317M | $361M | $415M | |
| Liabilities + Equity | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | · | $531M | |
| Shares Outstanding | 97,866,996 | 97,866,996 | 97,866,996 | 93,264,421 | 87,388,425 | 83,709,536 | 82,734,696 | 82,538,624 | 82,429,514 | 82,234,951 | 81,767,263 | 81,668,796 | 81,616,909 | 68,993,591 | · | 68,761,729 |
Cash Flow 10
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $2M | $2M | $3M | $3M | $4M | $5M | $5M | $8M | $5M | $5M | $5M | $5M | $5M | $6M | |
| Restructuring | · | · | · | · | · | $53M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-30M | $-23M | $-36M | $-31M | $-50M | $-48M | $-51M | $-53M | $-57M | $-50M | $-22M | $-35M | $-39M | $-36M | $-42M | $-48M | |
| CapEx | $106.0K | $92.0K | $60.0K | $433.0K | $0 | $114.0K | $540.0K | $3M | $3M | $2M | $1M | $239.0K | $1M | $2M | $624.0K | $614.0K | |
| Investing Cash Flow | $-30M | $64.0K | $58.0K | $40M | $43M | $56M | $31M | $84M | $52M | $-5M | $63M | $-103M | $13M | $23M | $-28M | $89M | |
| Stock Issued | $117M | $0 | $17M | $17M | $7M | $1M | $0 | $0 | $0 | $0 | $0 | $0 | · | · | $0 | · | |
| Net Stock Activity | · | $0 | · | · | · | $1M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $118M | $0 | $17M | $17M | $7M | $-1M | $56M | $0 | $322.0K | $192.0K | $514.0K | $0 | $118M | $0 | $619.0K | $80.0K | |
| Net Change in Cash | $58M | $-23M | $-19M | $26M | $-150.0K | $7M | $36M | $31M | $-5M | $-54M | $41M | $-138M | $92M | $-13M | $-69M | $41M | |
| Free Cash Flow | · | $-23M | · | · | · | $-48M | · | · | · | $-52M | · | · | · | $-38M | · | · |
Profitability 5
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | · | -136952.4% | |
| Net Margin | -153.3% | -882.4% | · | -333.0% | -1487.8% | -1633.5% | · | -101870.5% | -13178.8% | -5458.1% | · | -843.7% | -1395.6% | -497.8% | · | -132681.0% | |
| EBITDA Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | · | -136952.4% | |
| ROA | -8.1% | -12.1% | · | -9.5% | -17.9% | -21.6% | · | -14.9% | -14.6% | -13.7% | · | -8.7% | -7.2% | -9.0% | · | -8.9% | |
| ROE | -29.3% | -74.8% | · | -26.6% | -42.4% | -42.6% | · | -23.2% | -21.4% | -20.2% | · | -11.6% | -9.3% | -11.8% | · | -11.1% |
Liquidity & Solvency 4
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.2 | 3.2 | · | 2.9 | 2.8 | 3.1 | · | 3.7 | 3.9 | 4.6 | · | 6.1 | 8.1 | 5.7 | · | 10.1 | |
| Quick Ratio | 3.1 | 3.2 | · | 2.8 | 2.7 | 3.0 | · | 3.7 | 3.8 | 4.5 | · | 6.0 | 8.0 | 5.6 | · | 9.9 | |
| Debt / Equity | 0.5 | 12.4 | · | 4.4 | 3.0 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.5 | 10.7 | · | 4.0 | 2.7 | 0.8 | · | · | · | · | · | · | · | · | · | · |
Efficiency 2
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 7.2 | 1.8 | · | 1.8 | 8.6 | 12.3 | · | 0.0 | 0.4 | 4.7 | · | 4.2 | 1.9 | 12.2 | · | 0.2 |
Valuation (TTM) 14
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $26M | $19M | · | $16M | $9M | $6M | · | $7M | $10M | $19M | · | $18M | $19M | $23M | · | $19M | |
| Net Income TTM | $-122M | $-179M | · | $-217M | $-259M | $-268M | · | $-237M | $-215M | $-196M | · | $-190M | $-199M | $-209M | · | $-199M | |
| Market Cap | $317M | $242M | · | $324M | $192M | $97M | · | $281M | $385M | $610M | · | $637M | $672M | $500M | · | $842M | |
| Enterprise Value | $161M | $173M | · | $217M | $70M | $-69M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -2.5 | -1.2 | · | -1.3 | -0.7 | -0.4 | · | -1.2 | -1.7 | -2.9 | · | -3.0 | -2.9 | -2.4 | · | -4.2 | |
| P/S | 12.3 | 13.0 | · | 20.4 | 21.8 | 15.3 | · | 40.0 | 39.0 | 31.8 | · | 35.2 | 35.1 | 21.7 | · | 43.4 | |
| P/B | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | · | 2.0 | |
| P / Tangible Book | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | · | 2.0 | |
| P / Cash Flow | · | -10.5 | · | · | · | -2.0 | · | · | · | -12.2 | · | · | · | -14.0 | · | · | |
| P / FCF | · | -10.4 | · | · | · | -2.0 | · | · | · | -11.8 | · | · | · | -13.3 | · | · | |
| EV / EBITDA | -8.7 | -6.9 | · | -8.8 | -1.4 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | · | -7.5 | · | · | · | 1.4 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 6.2 | 9.3 | · | 13.7 | 8.0 | -10.9 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -40.7% | -84.6% | · | -74.4% | -141.8% | -280.2% | · | -84.5% | -57.6% | -34.8% | · | -33.7% | -34.8% | -41.9% | · | -23.7% |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenue | $41M | $32M | $78M | $20M | $26M |
| Operating Margin % | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% |
| Net Income | $-160M | $-237M | $-153M | $-220M | $-193M |
| Diluted EPS | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 |
Balance Sheet
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Debt / Equity | 2.1 | 0.4 | — | — | — |
| Current Ratio | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 |
| Quick Ratio | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 |
Cash Flow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Free Cash Flow | $-166M | $-219M | $-137M | $-181M | $-172M |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 239 filers · $327.2M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 41 (-2 vs prior Q) | 22 (-4 vs prior Q) | 76 (+20 vs prior Q) | 42 (-9 vs prior Q) | +67.4M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| TCG Crossover Management, LLC | $36,000,000 | 11,111,111 | 11.00% | Shares |
| RA CAPITAL MANAGEMENT, L.P. | $28,800,360 | 8,889,000 | 8.80% | Shares |
| Commodore Capital LP | $28,800,360 | 8,889,000 | 8.80% | Shares |
| ADAR1 Capital Management, LLC | $28,800,360 | 8,889,000 | 8.80% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $19,897,929 | 6,141,336 | 6.08% | Shares |
| Paradigm Biocapital Advisors LP | $18,100,665 | 5,586,625 | 5.53% | Shares |
| Opaleye Management Inc. | $12,512,653 | 3,861,930 | 3.82% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $11,658,618 | 3,598,339 | 3.56% | Shares |
| Woodline Partners LP | $11,519,810 | 3,555,497 | 3.52% | Shares |
| Vivo Capital, LLC | $11,519,010 | 3,555,250 | 3.52% | Shares |
| GordonMD Global Investments LP | $10,131,480 | 3,127,000 | 3.10% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $7,999,298 | 2,468,919 | 2.45% | Shares |
| Logos Global Management LP | $7,199,280 | 2,222,000 | 2.20% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $7,134,030 | 2,201,290 | 2.18% | Shares |
| STATE STREET CORP | $7,101,442 | 2,191,803 | 2.17% | Shares |
| GOLDMAN SACHS GROUP INC | $6,763,843 | 2,087,606 | 2.07% | Shares |
| TWO SIGMA INVESTMENTS, LP | $4,318,842 | 1,332,976 | 1.32% | Shares |
| Seven Fleet Capital Management LP | $4,310,820 | 1,330,500 | 1.32% | Shares |
| RAYMOND JAMES FINANCIAL INC | $4,201,156 | 1,296,653 | 1.28% | Shares |
| MARSHALL WACE, LLP | $4,044,048 | 1,248,163 | 1.24% | Shares |
| D. E. Shaw & Co., Inc. | $3,715,178 | 1,146,660 | 1.14% | Shares |
| KENNEDY CAPITAL MANAGEMENT LLC | $3,344,111 | 1,032,133 | 1.02% | Shares |
| MACKENZIE FINANCIAL CORP | $2,844,856 | 878,042 | 0.87% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $2,812,424 | 868,032 | 0.86% | Shares |
| Nantahala Capital Management, LLC | $2,762,748 | 852,700 | 0.84% | Shares |
| TWO SIGMA ADVISERS, LP | $2,509,405 | 1,224,100 | 0.77% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $2,407,158 | 742,950 | 0.74% | Shares |
| BlackRock, Inc. | $1,813,920 | 559,852 | 0.55% | Shares |
| MILLENNIUM MANAGEMENT LLC | $1,616,750 | 498,997 | 0.49% | Shares |
| Susquehanna Portfolio Strategies, LLC | $1,545,801 | 477,099 | 0.47% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,521,180 | 469,500 | 0.46% | Call option |
| Eversept Partners, LP | $1,486,541 | 458,809 | 0.45% | Shares |
| Casdin Capital, LLC | $1,441,800 | 445,000 | 0.44% | Shares |
| PEAK6 LLC | $1,346,029 | 415,441 | 0.41% | Shares |
| DIADEMA PARTNERS LP | $1,296,000 | 400,000 | 0.40% | Call option |
| BIT Capital GmbH | $1,056,240 | 326,000 | 0.32% | Shares |
| Cubist Systematic Strategies, LLC | $994,094 | 286,482 | 0.30% | Shares |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $878,642 | 271,186 | 0.27% | Shares |
| BANK OF AMERICA CORP /DE/ | $751,119 | 231,827 | 0.23% | Shares |
| LPL Financial LLC | $748,813 | 231,115 | 0.23% | Shares |
| Erste Asset Management GmbH | $736,000 | 230,000 | 0.22% | Shares |
| IEQ CAPITAL, LLC | $705,623 | 217,785 | 0.22% | Shares |
| Walleye Capital LLC | $595,703 | 183,859 | 0.18% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $558,900 | 172,500 | 0.17% | Put option |
| CITADEL ADVISORS LLC | $557,604 | 172,100 | 0.17% | Put option |
| DAFNA Capital Management LLC | $552,323 | 170,470 | 0.17% | Shares |
| Mariner, LLC | $548,500 | 169,291 | 0.17% | Shares |
| Green Alpha Advisors, LLC | $505,589 | 156,046 | 0.15% | Shares |
| PEAK6 LLC | $497,340 | 153,500 | 0.15% | Call option |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $490,555 | 151,406 | 0.15% | Shares |
| BARCLAYS PLC | $476,030 | 146,923 | 0.15% | Shares |
| ALLIANCEBERNSTEIN L.P. | $464,187 | 187,930 | 0.14% | Shares |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $445,030 | 137,355 | 0.14% | Shares |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $408,240 | 126,000 | 0.12% | Shares |
| Point72 Asset Management, L.P. | $405,758 | 125,234 | 0.12% | Shares |
| RHUMBLINE ADVISERS | $380,421 | 117,417 | 0.12% | Shares |
| JPMORGAN CHASE & CO | $376,528 | 117,665 | 0.12% | Shares |
| JANE STREET GROUP, LLC | $374,473 | 115,578 | 0.11% | Shares |
| FMR LLC | $348,384 | 107,526 | 0.11% | Shares |
| HSBC HOLDINGS PLC | $314,481 | 97,062 | 0.10% | Shares |
| Bank of New York Mellon Corp | $309,378 | 95,487 | 0.09% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $303,462 | 93,661 | 0.09% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $300,818 | 92,845 | 0.09% | Shares |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $300,226 | 92,094 | 0.09% | Shares |
| AMERICAN CENTURY COMPANIES INC | $300,011 | 92,596 | 0.09% | Shares |
| CWM, LLC | $259,352 | 105,001 | 0.08% | Shares |
| MORGAN STANLEY | $237,324 | 73,248 | 0.07% | Shares |
| CITADEL ADVISORS LLC | $229,392 | 70,800 | 0.07% | Call option |
| OSAIC HOLDINGS, INC. | $222,928 | 68,806 | 0.07% | Shares |
| SEI INVESTMENTS CO | $221,188 | 68,268 | 0.07% | Shares |
| Nuveen, LLC | $221,188 | 68,268 | 0.07% | Shares |
| Joel Isaacson & Co., LLC | $220,787 | 68,144 | 0.07% | Shares |
| JANE STREET GROUP, LLC | $218,376 | 67,400 | 0.07% | Put option |
| SIMPLEX TRADING, LLC | $207,275 | 63,974 | 0.06% | Shares |
| MetLife Investment Management, LLC | $182,140 | 56,216 | 0.06% | Shares |
| CITIGROUP INC | $182,052 | 56,189 | 0.06% | Shares |
| CITADEL ADVISORS LLC | $173,923 | 53,680 | 0.05% | Shares |
| MML INVESTORS SERVICES, LLC | $168,765 | 52,088 | 0.05% | Shares |
| GROUP ONE TRADING LLC | $163,131 | 50,349 | 0.05% | Shares |
| Creative Planning | $147,653 | 45,572 | 0.05% | Shares |
| China Universal Asset Management Co., Ltd. | $143,934 | 44,424 | 0.04% | Shares |
| WINTON GROUP Ltd | $141,588 | 43,700 | 0.04% | Shares |
| Vanguard Global Advisers, LLC | $138,876 | 42,863 | 0.04% | Shares |
| CANADA PENSION PLAN INVESTMENT BOARD | $137,376 | 42,400 | 0.04% | Shares |
| Graham Capital Management, L.P. | $134,369 | 41,472 | 0.04% | Shares |
| Quinn Opportunity Partners LLC | $129,600 | 40,000 | 0.04% | Shares |
| Invesco Ltd. | $128,178 | 39,561 | 0.04% | Shares |
| Vanguard Personalized Indexing Management, LLC | $124,108 | 38,305 | 0.04% | Shares |
| MERCER GLOBAL ADVISORS INC /ADV | $121,967 | 37,644 | 0.04% | Shares |
| Balyasny Asset Management L.P. | $121,947 | 37,638 | 0.04% | Shares |
| AXQ CAPITAL, LP | $118,104 | 36,452 | 0.04% | Shares |
| Nuveen Asset Management, LLC | $113,934 | 89,712 | 0.03% | Shares |
| SCS Capital Management LLC | $113,400 | 35,000 | 0.03% | Shares |
| Police & Firemen's Retirement System of New Jersey | $109,749 | 33,873 | 0.03% | Shares |
| Thrive Wealth Management, LLC | $108,540 | 33,500 | 0.03% | Shares |
| TWO SIGMA SECURITIES, LLC | $107,367 | 33,138 | 0.03% | Shares |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | $102,359 | 31,207 | 0.03% | Shares |
| CAPTRUST FINANCIAL ADVISORS | $98,159 | 30,296 | 0.03% | Shares |
| HORIZON KINETICS ASSET MANAGEMENT LLC | $89,683 | 27,680 | 0.03% | Shares |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $88,339 | 27,265 | 0.03% | Shares |
Company insiders 32 insiders · 13 officers · 15 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Gilmore Neil O'Neill | CEO | June 3, 2026 S | 248,313 | 0 | 1 | $-41,543 |
| MULLEN JAMES C | CEO | Jan. 3, 2022 S | 75,898 | 0 | 0 | $0 |
| Cynthia Collins | CEO | Feb. 9, 2021 S | 43,760 | 0 | 0 | $0 |
| Katrine Bosley | President and CEO | Jan. 8, 2019 S | 1,204,966 | 0 | 0 | $0 |
| Michelle Robertson | Chief Financial Officer | Jan. 11, 2022 S | 31,462 | 0 | 0 | $0 |
| Andrew A. F. Hack | Chief Financial Officer | Feb. 4, 2019 M | 0 | 0 | 0 | $0 |
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | July 28, 2026 S | 62,369 | 0 | 2 | $-15,133 |
| Bruce Eaton | EVP, Chief Business Officer | Dec. 22, 2021 A | 31,498 | 0 | 0 | $0 |
| Lisa Anne Michaels | EVP/Chief Medical Officer | Dec. 22, 2021 A | 22,675 | 0 | 0 | $0 |
| Mark S Shearman | EVP, Chief Scientific Officer | Dec. 22, 2021 A | 41,785 | 0 | 0 | $0 |
| Judith R Abrams | Chief Medical Officer | Oct. 28, 2019 A | 25,000 | 0 | 0 | $0 |
| Vickesh Myer | Chief Technology Officer | March 18, 2019 M | 0 | 0 | 0 | $0 |
| Gerald Frank Cox | Chief Medical Officer | Feb. 7, 2018 A | 4,000 | 0 | 0 | $0 |
| Elliott M. Levy | Director | June 17, 2026 A | — | 0 | 0 | $0 |
| David Scadden | Director | June 17, 2026 A | — | 0 | 0 | $0 |
| Bernadette Connaughton | Director | June 17, 2026 A | — | 0 | 0 | $0 |
| Jessica Hopfield | Director | June 17, 2026 A | 22,700 | 0 | 0 | $0 |
| Andrew Hirsch | Director | June 17, 2026 A | — | 0 | 0 | $0 |
| Emma Reeve | Director | Sept. 3, 2021 A | — | 0 | 0 | $0 |
| Meeta Chatterjee | Director | June 3, 2021 A | — | 0 | 0 | $0 |
| Boris Nikolic | Director | June 15, 2018 A | 35,000 | 0 | 0 | $0 |
| Douglas G. Cole | Director | Aug. 17, 2017 J | 3,171 | 0 | 0 | $0 |
| Kevin Bitterman | Director | June 15, 2017 A | 2,797,144 | 0 | 0 | $0 |
| Alexis Borisy | Director | June 15, 2017 A | 0 | 0 | 0 | $0 |
| John Mendlein | Director | June 15, 2017 A | — | 0 | 0 | $0 |
| Kevin P Starr | 10% owner | Sept. 6, 2016 S | 0 | 0 | 0 | $0 |
| bng0, LLC | 10% owner | Feb. 8, 2016 C | 2,649,572 | 0 | 0 | $0 |
| Patrick Thomas Ellinor II | — | Aug. 6, 2026 A | — | 0 | 0 | $0 |
| Amy Parison | — | Aug. 3, 2026 S | 14,292 | 0 | 2 | $-3,002 |
| Akshay Vaishnaw | — | June 3, 2021 A | — | 0 | 0 | $0 |
| Charles Albright | — | Dec. 15, 2020 M | 24,907 | 0 | 0 | $0 |
| Alexandra Glucksmann | — | March 15, 2017 M | 117,788 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Polaris Venture Partners VI, L.P. (“PVP VI”), Polaris Venture Founders’ Fund VI, L.P. (“PVPFF VI”), Polaris Venture Management Co. VI, L.L.C. (“PVM VI”), Jonathan A. Flint (“Flint”), Terrance G. McGuire (“McGuire”), Brian Chee (“Chee”), David Barrett (“Barrett”), Amir Nashat (“Nashat”), Bryce Youngren (“Youngren”) ×4 filings | Sept. 18, 2017 | — | Initial filing | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 28 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| GNOM · Global X Funds | 0.34% | 54,725 NS | May 31, 2026 | N-PORT |
| BIB · ProShares Trust | 0.02% | 3,611 NS | May 31, 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0.02% | 1,527 NS | May 31, 2026 | N-PORT |
| RSSL · Global X Funds | 0.01% | 42,610 NS | April 30, 2026 | N-PORT |
| ITWO · ProShares Trust | 0.01% | 4,633 NS | May 31, 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0.01% | 476,309 NS | May 31, 2026 | N-PORT |
| UWM · ProShares Trust | 0.01% | 3,622 NS | May 31, 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0.00% | 32,379 NS | May 31, 2026 | N-PORT |
| URTY · ProShares Trust | 0.00% | 3,660 NS | May 31, 2026 | N-PORT |
| HDG · ProShares Trust | 0.00% | 92 NS | May 31, 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.00% | 2,922 NS | May 31, 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0.00% | 96,350 NS | May 31, 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | July 15, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | — | — | July 15, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | July 15, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | — | — | July 15, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | July 15, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | July 15, 2026 | Daily |
| IWV · iShares Trust | — | — | Aug. 18, 2026 | Daily |
| IWN · iShares Trust | — | — | Aug. 17, 2026 | Daily |
| IWO · iShares Trust | — | — | Aug. 18, 2026 | Daily |
| IWM · iShares Trust | — | — | Aug. 18, 2026 | Daily |
| IBB · iShares Trust | — | — | Aug. 18, 2026 | Daily |
| IWC · iShares Trust | — | — | Aug. 18, 2026 | Daily |
| PRFZ · Invesco Exchange-Traded Fund Trust | — | — | July 13, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | — | — | July 20, 2026 | Daily |
| IBBQ · Invesco Exchange-Traded Fund Trust … | — | — | July 20, 2026 | Daily |
| QQQS · Invesco Exchange-Traded Fund Trust … | — | — | July 20, 2026 | Daily |